Biogen
BIIBAlgoritmens signaler
- ›Starkt 3m-momentum (+25.7%)
- ›Starkt 6m-momentum (+35.6%)
- ›Starkt 12m-momentum (+67.5%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›+70% från 52v-botten
- ›Ökad handelsvolym (+49%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsBiogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
2 d sedanBiogen Inc. (BIIB) Stock Forecasts Yahoo Finance
Yahoo FinanceBiogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says - Yahoo Finance
2 d sedanBiogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says Yahoo Finance
Yahoo FinanceBiogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
2 d sedanDiranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab
BiogenGlobeNewswireBiogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) - Seeking Alpha
3 d sedanBiogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) Seeking Alpha
Seeking AlphaBiogen slår förväntningarna - snävar in vinstprognosintervall
3 d sedanAmerikanska läkemedelsbolaget Biogen redovisar en bättre än förväntad rapport för det tredje kvartalet.Omsättningen steg 10,2 procent till 2,80 miljarder dollar (2,54). Utfallet kan jämföras med Facts
BiogenFinwireAnalytikerkonsensus inför dagens USA-rapporter
4 d sedanSammanställningen nedan avser det globala börsinformationsföretaget Factsets analytikerkonsensus för amerikanska bolag som senare i dag lämnar delårsrapport.Om bolaget har lämnat egen guidning anges d
BiogenFinwireBIIB Stock Earnings Preview: What’s Next for Biogen as its MS Business Wanes? - CMC Markets
4 d sedanBIIB Stock Earnings Preview: What’s Next for Biogen as its MS Business Wanes? CMC Markets
CMC MarketsBiogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued - Yahoo Finance
4 d sedanBiogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued Yahoo Finance
Yahoo FinanceBiogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data - Yahoo Finance
4 d sedanBiogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data Yahoo Finance
Yahoo FinanceBiogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
2026-10-19Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profile Additional presentations to hig
BiogenGlobeNewswireJP Morgan höjer Biogen till övervikt (neutral), riktkurs 300 dollar (210)
2026-10-12JP Morgan höjer Biogen till övervikt (neutral), riktkurs 300 dollar (210)newsroom@finwire.seNyhetsbyrån Finwire
BiogenFinwireBiogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom - Yahoo Finance
2026-10-12Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom Yahoo Finance
Yahoo FinanceBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
2026-10-02Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and i
BiogenGlobeNewswireBiogen visar positiva fas 3-data för Empaveli hos ungdomar
2026-09-18Amerikanska läkemedelsbolaget Biogen uppger att en förutbestämd subgruppsanalys från fas 3-studien Valiant visar att Empaveli minskade proteinuri och stabiliserade njurfunktionen hos ungdomar med C3G
BiogenFinwirePhase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
2026-09-17EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, base
BiogenGlobeNewswireStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
2026-09-03–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with
BiogenGlobeNewswire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.